Investors inject $11m into baldness therapy co
This article was originally published in Clinica
Executive Summary
Boston, Massachusetts start-up Follica has attracted $11m in series B financing to further the development of its treatment for androgenetic alopecia, the most common form of hair loss. The technology, which originated at the University of Pennsylvania, works by stimulating the growth of entirely new hair follicles, said the company. In conjunction with the financing, which was led by Polaris Venture Partners, Follica also announced several appointments. Former Genentech CEO Kirk Raab and principal of Polaris Dr Kevin Bitterman joins the board of directors; Scott Kellog, formerly of Sontra Medical, Ultracision and Ethicon Endosurgery, is now Follica's vice-president of operations; and Dr Stephen Prouty is promoted to vice-president of research.